This study confirmed a reduction in cellular glucose influx in MCF-7 and ZR-75-1 breast cancer cells, indicating involvement of SGLT-2 inhibition in the anticancer effects of canagliflozin and dapagliflozin on breast cancer. Here, SLC5A2 is linked to breast carcinoma.